Bats are known as natural hosts for highly pathogenic viruses such as MERS- and SARS-related coronaviruses, as well as the Marburg and Nipah viruses. In contrast to the severe and often fatal disease outcomes these viruses cause in humans, bats generally do not show obvious signs of viral illness following infection. An international research team led by Dr. Max Kellner and Prof. Josef Penninger, Scientific Director of the Helmholtz Centre for Infection Research (HZI), has developed an innovative organoid research platform that allowed them to closely investigate the cellular antiviral defense mechanisms of mucosal epithelial tissues of bats. The results have now been published in Nature Immunology and could pave the way for the development of new therapies against viral diseases.

In a recent study, a research team from the Medical University of Vienna has gained new insights into post-COVID syndrome (PCS) and the relevance of a healthy gastrointestinal tract. The study, which was recently published in the journal Allergy, shows that PCS patients have altered inflammatory markers and a disturbed intestinal barrier, which could contribute to the development of post-viral fatigue.

Since the COVID-19 pandemic, there has been a decline in U.S. vaccine uptake, while widespread misinformation and distrust make it challenging to craft effective public health responses. In a new paper, University of Illinois Urbana-Champaign researchers discuss three case studies exemplifying different vaccine attitudes and behaviors. Their findings underscore the need for flexible approaches to reach diverse audiences with disease prevention strategies. 

Researchers found that nearly 40% of pediatric patients with long COVID reported feeling significant symptoms of anxiety or depression.

Tourism entrepreneurs in Sub-Saharan Africa are not only weathering the storm of environmental uncertainty but are thriving amid adversity in emerging economies, according to a new study from the University of Surrey.  

About The Study: In this large cohort study of patients hospitalized with nonsevere COVID-19, there was no clinically meaningful difference in outcomes with early antibiotic treatment. Given the risks associated with unnecessary antibiotic treatment, these results argue against routine antibiotic use in this population.

Cannabidiol – which lacks the psychotropic effects of cannabis – has been shown to have beneficial effects on inflammation in myocarditis and pericarditis models. 

A prospective placebo-controlled trial was conducted with an oral pharmaceutically manufactured (GMP) cannabidiol formulation in patients at high risk of cardiovascular events who were hospitalised for non-critical COVID-19 infection.  

GMP-cannabidiol formulation was well tolerated with a similar low rate of overall and cardiac side effects as placebo, supporting its study in further trials.  

Researchers surveyed 4,177 adult American citizens in the United States. Participants provided opinions about four scenarios that featured individuals with distinct life circumstances and names that were racially/ethnically identifiable. The individual in the first scenario had “a genetic condition that destroyed his kidneys” and necessitated a kidney transplant. The second had “worked in a coal mine all his life” and needed a lung transplant because of black lung disease. The third was “very ill with COVID-19,” had not been vaccinated against COVID-19 and needed a lung transplant. And the fourth had alcohol use disorder and needed a liver transplant.

Federal or statewide policies that help families in economic crises could dramatically reduce the rate of child abuse and neglect, according to a new study from the University of Georgia.

New Haven, Conn. — Most vaccines — and boosters — are injected directly into muscle tissue, usually in the upper arm, to kickstart the body’s immune system in the fight against disease. But for respiratory diseases like COVID-19, it can be important to have protection right where the virus enters: the respiratory tract. 

In a new study, Yale researchers found that nasal vaccine boosters can trigger strong immune defenses in the respiratory tract, even without the help of immune-boosting ingredients known as adjuvants. The findings, researchers suggest, may offer critical insights into developing safer, more effective nasal vaccines in the future.